サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1467745

非アルコール性脂肪性肝炎市場：薬剤タイプ、疾患原因、販売チャネル、エンドユーザー、地域別、2024～2032年

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
非アルコール性脂肪性肝炎市場：薬剤タイプ、疾患原因、販売チャネル、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非アルコール性脂肪性肝炎市場規模は2023年に16億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて24.18%の成長率（CAGR）を示し、市場は2032年までに115億米ドルに達すると予測しています。NASHの有病率の上昇、早期診断と治療に関する意識の高まり、人工知能（AI）と機械学習（ML）技術の統合は、市場を牽引する主要要因のいくつかを表しています。

非アルコール性脂肪性肝炎は、インスリン抵抗性、過体重、メタボリックシンドロームによって引き起こされる進行性の非アルコール性脂肪性肝疾患（NAFLD）を指します。その症状は、疲労感や脱力感、体重減少、黄疸、皮膚のかゆみ、クモ状静脈、肝臓肥大、集中力の欠如、体液貯留、痛みや腫れなどの腹部不快感を伴う。健康診断、血液試験、肝生検、磁気共鳴画像法（MRI）、超音波試験、コンピューター断層撮影法（CT）など、複数の試験法によって診断されます。NASHの治療には、薬剤療法、肝移植、定期的な運動や健康的な食事などの生活習慣の改善などがあります。これらの治療法は、肝脂肪の蓄積を抑え、肝機能を改善し、炎症を抑え、肝障害を最小限に抑えるのに役立ちます。また、患者の生活の質を高め、長期的な転帰を改善し、肥満や高血圧などの他の健康問題をよりよく管理できるようにします。

非アルコール性脂肪性肝炎市場の動向：

遺伝、座りがちなライフスタイル、不健康な食習慣、肥満、2型糖尿病などによるNASHの有病率の上昇は、市場成長を促進する主要要因の1つです。これに伴い、NASH治療は症状の緩和、寿命の延長、早死の防止、肝臓の健康増進、全体的な健康増進を目的として患者に広く採用されており、これが市場成長の推進力となっています。さらに、医療費を削減し、肝移植の必要性をなくし、高血圧、心血管疾患（CVDs）、がん、肝硬変、肝不全などの将来の合併症を予防するために、NASHの早期診断と治療に関する大衆の意識が高まっていることが、市場成長の原動力となっています。さらに、MRIや一過性エラストグラフィ（TE）などの非侵襲的画像診断技術をNASHのモニタリングや診断に活用することで、患者の快適性を高め、コンプライアンスを向上させ、合併症のリスクを低減し、臨床転帰を改善することが、市場成長にプラスの影響を与えています。これに加えて、個別化治療の開発、診断精度の向上、疾患進行予測のための人工知能（AI）と機械学習（ML）の統合が、市場成長に好影響を与えています。さらに、質の高い治療へのアクセスを提供し、先進的な治療の市場開拓を支援するためのさまざまな政府イニシアチブの実施が、市場の成長を促進しています。その他の要因としては、高齢者人口の増加、医療費の増加、広範な研究開発活動、医療産業の著しい成長、非侵襲的な治療オプションに対する需要の増加などが挙げられ、市場の成長を促進すると予想されます。

本レポートで扱う主要質問

  • 世界の非アルコール性脂肪性肝炎市場の規模は？
  • 2024～2032年にかけての世界の非アルコール性脂肪性肝炎市場の予想成長率は？
  • 世界の非アルコール性脂肪性肝炎市場を牽引する主要因は？
  • COVID-19が世界の非アルコール性脂肪性肝炎市場に与えた影響は？
  • 非アルコール性脂肪性肝炎の世界市場における薬剤タイプ別の区分は？
  • 疾患原因別の非アルコール性脂肪性肝炎の世界市場内訳は？
  • 販売チャネル別の非アルコール性脂肪性肝炎の世界市場内訳は？
  • エンドユーザー別の非アルコール性脂肪性肝炎の世界市場内訳は？
  • 世界の非アルコール性脂肪性肝炎市場における主要地域は？
  • 世界の非アルコール性脂肪性肝炎市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 非アルコール性脂肪性肝炎の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • ビタミンEとピオグリタゾン
  • オカリバ
  • エラフィブラノール
  • セロンサチブ
  • セニクリビロク
  • その他

第7章 市場内訳：疾患原因別

  • 高血圧症
  • 心臓病
  • 高脂血症
  • 2型糖尿病
  • 肥満症

第8章 市場内訳：販売チャネル別

  • 病院薬局
  • オンラインプロバイダー
  • 小売薬局

第9章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • 在宅ケア

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
図表

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2023
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2023
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million US$), 2024-2032
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million US$), 2024-2032
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
目次
Product Code: SR112024A7397

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.

Drug Type Insights:

Vitamin E and Pioglitazone

Ocaliva

Elafibranor

Selonsertib

Cenicriviroc

Others

The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.

Disease Cause Insights:

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.

Sales Channel Insights:

Hospital Pharmacy

Online Providers

Retail Pharmacy

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.

End User Insights:

Hospitals

Clinics

Homecare Settings

A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2. What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2024-2032?
  • 3. What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4. What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9. What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10. Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.